Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea-pigs.
1. The effects in vitro and in vivo of three fibric acid derivatives, clofibrate (CFB), bezafibrate (BFB) and gemfibrozil (GFB) on some enzyme activities related to fatty acid biosynthesis, namely palmitoyl-CoA synthetase and hydrolases (microsomal and cytosolic), NADH and NADPH cytochrome c reductases and acyl-CoA elongases were investigated in guinea-pigs. 2. The three fibrates inhibited acyl-CoA elongation in vitro, irrespective of the substrate of elongation used (saturated, monounsaturated, polyunsaturated) and with an order of potency GFB > BFB > CFB. In the case of GFB, inhibition occurred at concentrations that can be reached in vivo. 3. Microsomal palmitoyl-CoA hydrolase and synthetase were also inhibited in vitro (GFB > or = BFB > CFB), whereas NADH cytochrome c reductase activity was increased by GFB. Nevertheless, the magnitude of changes were lower than those observed in elongation activities. 4. Treatment with fibrates did not produce peroxisomal proliferation in guinea-pigs, as measured by peroxisomal beta-oxidation activity and liver weight/body weight ratio. Nevertheless, fibrates provoked a reduction in plasma cholesterol and triglycerides, at least in GFB- and BFB-treated animals. 5. Fatty acid elongation was significantly modified by GFB treatment in vivo. The remaining enzyme activities studied were only slightly changed by fibrate treatment. 6. Treatment with BFB and to a lesser extent with CFB, increased the relative proportion of MUFA (palmitoleic and oleic acids) in microsomal phospholipids, whereas PUFA (mainly linoleic acid) decreased. GFB behaved differently, increasing palmitic and linoleic acids and decreasing stearic and oleic acids. The latter changes are attributable to an inhibition of elongation activity by GFB. 7. The changes observed after fibrate treatment in both rats and guinea-pigs, as they are not directly related to peroxisome proliferation, could be more reliably extrapolated to man than those observed only in rats.
Vázquez
M
M
Dept. Farmacologia y Quimica Terapeutica, Facultad de Farmacia, Núcleo Universitario de Pedralbes, Barcelona, Spain.
Alegret
M
M
López
M
M
Rodríguez
C
C
Adzet
T
T
Merlos
M
M
Laguna
J C
JC
D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology; D002994:Clofibrate / Q000494:pharmacology; D064429:Fatty Acid Synthases / Q000378:metabolism*; D005227:Fatty Acids / Q000032:analysis*; D015248:Gemfibrozil / Q000494:pharmacology; D006168:Guinea Pigs; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects* / Q000201:enzymology; D009245:NADH Dehydrogenase / Q000378:metabolism; D009251:NADPH-Ferrihemoprotein Reductase / Q000378:metabolism; D010170:Palmitoyl-CoA Hydrolase / Q000378:metabolism*; D010743:Phospholipids / Q000032:analysis*
D005227:Fatty Acids; D000960:Hypolipidemic Agents; D010743:Phospholipids; D009251:NADPH-Ferrihemoprotein Reductase; D009245:NADH Dehydrogenase; D064429:Fatty Acid Synthases; D010170:Palmitoyl-CoA Hydrolase; D002994:Clofibrate; D015248:Gemfibrozil; D001629:Bezafibrate